A case report highlights the severe symptoms and protocol for primary plasma cell leukemia, indicating urgency in diagnosis and treatment.
Primary Plasma Cell Leukemia (pPCL) is a rare and highly aggressive plasma cell disorder, accounting for less than 2% of multiple myeloma cases. It is defined by ≥20% circulating plasma cells in peripheral blood or an absolute count of ≥2 × 10⁹/L, without prior evidence of multiple myeloma. Diagnosis is frequently delayed due to nonspecific clinical manifestations that may mimic severe infections or other malignancies. A 43-year-old male presented with fever, generalized fatigue, progressive lower limb weakness, decreased appetite, weight loss, constipation, and hypotension (70/50 mmHg). Laboratory findings showed leukocytosis (30,600/μL), anemia (Hb 8.7 g/dL), and normal platelets. Peripheral blood smear demonstrated plasmacytoid lymphocytes with rouleaux formation. Serum protein electrophoresis revealed monoclonal gammopathy, and urine tested positive for Bence-Jones proteins. Imaging studies identified multiple lytic bone lesions, while spinal MRI suggested transverse myelitis. Bone marrow aspirate revealed 57% plasma cells and 6% plasmablasts, with 32 plasma cells identified in peripheral blood. Initial management included fluid resuscitation, vasopressors, empirical antibiotics, and packed red cell transfusion. VRD-based induction chemotherapy (Bortezomib, Lenalidomide, Dexamethasone) was planned. Unfortunately, the patient deteriorated rapidly, developing severe sepsis and multi-organ failure before therapy could be initiated. This case underscores the importance of early recognition of pPCL in patients with systemic symptoms and abnormal peripheral smear findings. A combination of hematologic evaluation and bone marrow assessment is essential for diagnosis. VRD remains the preferred first-line regimen due to its rapid cytoreductive effect and its role as a bridge to autologous stem cell transplantation. Nevertheless, prognosis remains poor when diagnosis and treatment are delayed. pPCL represents a hematologic emergency with aggressive clinical behavior, and early warning signs such as paraparesis and hypotension must be promptly identified to allow rapid diagnosis and timely therapy.
No takes yet. Share an insight, caveat, or question.
Yunarvika et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: